Ova-Gest

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ova-Gest

Property Description
Active ingredient Progesterone
Form Soft Gel Capsule
Pharmacological class Progestin/Progestogen (Steroid Hormone)
General purpose Foundational hormonal support for deficiency
Origin Natural Micronized (molecularly identical to endogenous hormone)

The Identity and Classification of Ova-Gest

Ova-Gest is a prescription medication containing progesterone, which is chemically defined as a natural female sex hormone. It is classified within the pharmacological category of progestogens or progestins, serving as an essential steroid hormone replacement. The progesterone in this formulation is molecularly identical to the endogenous progesterone produced naturally in the human body. This natural identity is fundamental to the hormone's functioning within the reproductive system. Unlike certain older, structurally modified synthetic progestins, this preparation is designed to directly supplement the levels of the body's own hormone.


Composition and Unique Micronized Form

The medication is supplied as an oral soft gel capsule, containing the progesterone suspended in an oily base. The active ingredient is prepared using micronization, a specialized pharmaceutical technique that reduces the progesterone particles to a very fine size. This micronized form is employed to address the low absorption of standard, non-micronized progesterone when taken orally. The use of this specific micronized technology enhances bioavailability, which is a standard approach for achieving therapeutic effects with oral progesterone. The soft capsule format is a differentiating factor, positioned for use in adult women requiring stabilization of the hormonal environment.


General Purpose: Foundational Hormonal Support

The core purpose of Ova-Gest is to provide foundational hormonal support for conditions characterized by an insufficient level of natural progesterone. The steroid hormone works by binding to progesterone receptors in target tissues, stabilizing the hormonal environment and promoting specific changes in tissues such as the endometrium (uterine lining). This action is essential for regulating the menstrual cycle and ensuring the body is physiologically prepared. This process provides luteal phase support in reproductive health contexts. Moreover, it plays a balancing role, opposing the proliferative effects that unopposed estrogen can exert on the uterine lining.

Regulatory References

  1. progestogens or progestins

What side effects are possible with Ova-Gest?

Possible Side Effects and Safety Information

Ova-Gest (micronized progesterone) carries a documented safety profile derived from regulatory and clinical sources. The adverse reactions are primarily observed across the gastrointestinal, nervous, and reproductive systems.

Adverse Reactions Summary

Category Common Side Effects (Reported Incidence ≥ 1/100)
Gastrointestinal Nausea, vomiting, abdominal bloating, stomach cramps
Nervous System Headache, dizziness, somnolence (drowsiness), fatigue
Reproductive/Breast Breast tenderness or pain, irregular vaginal bleeding or spotting
Other Fluid retention, mood changes (e.g., anxiety or depression)

Serious Safety Considerations

The most significant and serious risks associated with progestin therapy include an increased risk of thromboembolic events (blood clots, stroke, pulmonary embolism) and an increased risk of breast cancer, particularly with prolonged use or when combined with estrogen. Severe hypersensitivity reactions, though rare, have also been documented.

Restrictions and Monitoring

The use of Ova-Gest is contraindicated or requires particular caution in individuals with a history of or current conditions such as breast cancer, unexplained vaginal bleeding, liver disease, or certain heart disorders. Close medical monitoring is advised for patients with diabetes or asthma, as well as those with kidney or heart problems. Patients should be aware that the medication may cause drowsiness and should use caution when operating machinery. Pregnancy and breastfeeding require careful medical consultation due to potential risks, though usage may be considered in life-threatening situations where benefits outweigh the risks.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes specific, dose-related clinical manifestations that may indicate an excessive exposure to progesterone. This profile is defined by central nervous system (CNS) symptoms that serve as signs of overdosage.

Documented Overdose Manifestations

Overdosage is typically characterized by the appearance of certain non-fatal, dose-related symptoms. Documented manifestations, consistent with regulatory labeling, include somnolence (drowsiness), dizziness, and euphoria. The official information also notes that dysmenorrhoea (altered or painful menstruation) may be present. These specific symptoms are classified as signs of overdosage in the context of the product's use.

Mandated Emergency Actions

In all suspected cases of overdosage, immediate medical attention must be sought. The required emergency response is strictly defined by regulatory authorities. Treatment procedures involve discontinuation of the product along with the mandatory institution of appropriate symptomatic and supportive care. Management protocols require continuous observation of the patient's condition. The official labeling confirms that no specific antidote is known for progesterone overdosage, reinforcing the necessity of defined supportive treatment. The presentation of documented overdose signs triggers the immediate need for professional medical assessment.

Therapeutic Uses of Ova-Gest

What Ova-Gest Treats: Main Uses and Benefits

Ova-Gest is used in situations involving certain distressing symptoms and relief across specific clinical domains characterized by acute discomfort and significant symptom expression. This class of agents is used to manage a variety of conditions, including irregular menstruation and abnormal uterine bleeding, which are marked by fluctuating and distressing symptoms.

This medication is commonly used to help with symptomatic management when symptoms related to systemic imbalance intensify or appear suddenly, creating noticeable interference with daily stability. It is relevant in clinical settings marked by heightened systemic burden and periods of increased physiological tension. The medication is relevant in conditions involving recurrent or episodic manifestations.

“Ova-Gest supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”

Ova-Gest is applied in addressing symptom clusters that may become intense or disruptive, and is relevant in situations where symptoms lead to temporary functional strain. It provides support that helps ease the overall symptom burden by being applied across domains where additional symptomatic support is needed. It may assist with managing symptoms that interfere with daily comfort and supports general well-being during symptomatic phases.


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH StatPearls on Progestins

Eligibility and Restrictions for Use

Who can and cannot use Ova-Gest?

Ova-Gest (micronized progesterone capsules) is officially designated for use in Adult Women, specifically premenopausal and postmenopausal populations. Regulatory agencies define stringent health conditions and physiological states under which the medicine must not be used, establishing formal population exclusions.

Contraindicated Populations (Absolute Prohibition)

Individuals are explicitly prohibited from using Ova-Gest if they have:

  • A known or suspected progestin-dependent malignancy, such as breast cancer.
  • A history of arterial or venous thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, or stroke).
  • Severe liver disease or hepatic impairment.
  • Undiagnosed abnormal genital bleeding.
  • Hypersensitivity to progesterone or any capsule ingredients.

Population Eligibility Restrictions

Population Group Official Regulatory Status
Pregnancy Contraindicated in known or suspected pregnancy.
Lactation (Breastfeeding) Generally Not Recommended by regulators.
Pediatric Patients (Under 18) Safety and effectiveness Not Established for this age group.
Geriatric Patients (Over 65) Clinical data is Insufficient to establish a differential response.

Conditional use restrictions also apply, requiring careful observation for patients with conditions sensitive to fluid retention, including asthma, migraine, epilepsy, or renal dysfunction.

What should I know about interactions with other medicines?

Ova-Gest Interactions with other medicines and products

Official regulatory documents describe a set of drug-drug interactions that primarily affect the level of Ova-Gest in the body, which is metabolized by the CYP3A4 enzyme system in the liver. Concomitant use with specific medicine categories is subject to caution or restrictions based on their potential to interfere with this metabolism.

Documented Interacting Medicines and Categories

  • Enzyme Inducers: Strong inducers of the CYP3A4 enzyme, such as certain anticonvulsants (e.g., carbamazepine, phenytoin) and select antibiotics (e.g., rifampin), may cause a reduction in the plasma concentration of Ova-Gest, potentially leading to a loss of the desired effect. Caution and monitoring are advised for these combinations.
  • CYP3A4 Inhibitors: Medicines that inhibit the CYP3A4 enzyme may increase the exposure of Ova-Gest, requiring careful monitoring.
  • Gastric pH Modifiers: Products that reduce stomach acid, such as Proton Pump Inhibitors (PPIs), may decrease the absorption of Ova-Gest, thus lowering its bioavailability. Official labeling implies a need for separation in administration timing or close observation.
  • Hormonal Therapies: Co-administration with other hormonal medicines, such as estrogens, may alter the overall hormonal balance and affect the actions of both treatments.

Interaction Constraints

The primary constraints involve the risk of reduced efficacy when taken with enzyme-inducing medicines and the need to consider altered absorption when co-administered with gastric acid reducers.

Mechanism of Action

Ova-Gest acts as a selective agonist at the progesterone receptor (PR), a nuclear receptor found primarily within the reproductive tract tissues, including the endometrium and ovaries. Following cellular entry, the compound binds to and activates the cytosolic PR, displacing heat shock proteins.

This complex then undergoes dimerization and translocates to the nucleus, where it binds to progesterone response elements (PREs) in the promoter regions of target genes. This binding modulates gene transcription, specifically promoting the expression of genes associated with endometrial differentiation and secretory changes, and concurrently repressing genes related to proliferation. Intracellularly, this altered transcriptional profile influences the activity of key signaling cascades, including the MAPK/ERK pathway and the AKT pathway, leading to changes in protein synthesis and cellular function. System-level consequences include the induction of a fully developed secretory endometrium and the suppression of the hypothalamic-pituitary-ovarian (HPO) axis via negative feedback, reducing the release of gonadotropins.

Dosage and Administration Information

How to Use Ova-Gest

Ova-Gest (micronized progesterone oral capsule) is administered exclusively via the oral route (by mouth). Its use follows specific, time-bound protocols rather than continuous daily dosing.


Official Dosing and Schedule

Use Regimen (Adult) Labeled Daily Dose Duration and Frequency
Secondary Amenorrhea 400 mg Once daily for 10 days.
Endometrial Prophylaxis 200 mg Once daily for 12 consecutive days per 28-day cycle.

Administration Requirements

  • Timing: The capsule should be taken as a single dose at bedtime. This timing is specified to align with the drug’s pharmacokinetic profile and administration requirements.
  • Method: The capsule must be swallowed whole with a full glass of water. Patients are often advised to take the capsule while in a standing or upright position to prevent difficulty swallowing.

Use Protocol

  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; patients are instructed not to double the dose to make up for a missed one.
  • Special Populations: Use of the oral capsule is generally not recommended in the pediatric population. The use in patients with renal dysfunction requires caution and careful monitoring.

Recent Clinical Evidence

Ova-Gest: Recent Clinical Evidence

Study Design and Findings

Research reports focus on the outcomes of studies designed to measure changes in symptoms. Investigations centered on various clinical endpoints, including joint swelling, pain reports, and patient-reported functionality metrics.

Multiple studies evaluated whether the combination of this agent with standard care was associated with changes in joint pain metrics. The design of these trials varied, from small, single-center pilots to larger, multi-national randomized controlled trials. Outcomes across these studies were mixed.

  • Early-Stage Disease: One study specifically reported findings that suggested an outcome in patients with early-stage disease, measured via a reduction in a specific disease activity score.
  • Established Disease: Trials in patients with established, chronic disease explored different dosing regimens. These studies indicated a range of response rates when measuring improvements in physical function scores.
  • Comparison Studies: Studies compared the drug profile to older treatments, focusing on changes in disease progression markers. These studies aimed to evaluate whether differences existed in the rates of change for these markers over a 12-month period.

Tolerability and Special Populations Data

Patient-reported data documented various experiences among participants. Studies on outcomes following treatment cessation have not been comprehensively reported. In clinical trials, researchers monitored the frequency and nature of all adverse events.

Safety Data Limitations

Studies monitored outcomes in participants with concurrent heart conditions; however, long-term safety data remains limited. Studies did not include participants who were pregnant or breastfeeding. Research has not yet evaluated outcomes in pediatric populations.

Research evaluated whether the drug was associated with changes in flare-up frequency and explored its relationship to metrics of quality of life. Findings in this area were inconsistent. Studies explored different initial dosing strategies and reported outcomes associated with each therapeutic window.

Although research is ongoing, preliminary data indicated that this new formulation was associated with a change in pain reports, even in resistant cases. Further studies are being conducted to confirm these preliminary observations and evaluate the long-term profile of this new formulation.

Frequently Asked Questions (FAQ)

Common questions about Ova-Gest (FAQ)


Q: Is Ova-Gest the same kind of medicine as other common treatments for this condition?

Official documents describe Ova-Gest as containing micronized progesterone, which is chemically identical to the progesterone produced naturally by the human body. This structure is a key difference from certain older, structurally modified synthetic progestins that are sometimes used for similar health concerns.


Q: Does Ova-Gest interact with common pain relievers like ibuprofen?

Official drug interaction information for micronized progesterone generally does not list ibuprofen, or similar non-prescription pain relievers, as a documented interaction that requires a change in dosing. However, regulatory best practice is to review all medications, including non-prescription products, with a healthcare professional.


Q: Does Ova-Gest interact with common vitamins or herbal supplements?

Official sources caution that certain herbal products, such as St. John’s Wort, may cause Ova-Gest to be less effective. This happens because these supplements can speed up the drug’s metabolism (how the body breaks it down). Patients are generally advised to consult with their healthcare provider before combining any herbal supplements or vitamins with this medication.


Q: How does Ova-Gest compare to older medications used for this purpose?

Ova-Gest contains micronized progesterone, which is chemically identical to the hormone produced by the body. Regulatory documents describe the structural differences between this natural, micronized formulation and certain older synthetic progestins.


Q: How long can a person expect to keep taking Ova-Gest?

The duration of treatment varies based on the specific condition being addressed. The medication is prescribed in time-bound protocols (such as 10 or 12 consecutive days per cycle) rather than as a continuous daily treatment. The overall length of time a person remains on this therapy is determined by their prescribing healthcare provider.


Q: Can Ova-Gest affect my mood or energy levels?

Official documents list several central nervous system reactions, including mood swings, irritability, depression, and fatigue, as possible adverse reactions. The medication may also cause somnolence (drowsiness) or dizziness. Individuals using this medication should be aware of these potential effects.


Q: What should I do if I notice a side effect from Ova-Gest?

Patients are generally advised to contact their healthcare provider immediately if they experience any serious or concerning side effects, such as signs of a blood clot or severe depression. For all other side effects, regulatory guidance advises consulting a healthcare professional. The FDA has a voluntary reporting program for serious side effects called MedWatch.


Q: Is Ova-Gest a long-term treatment or short-term?

The official usage of Ova-Gest involves time-bound protocols lasting approximately 10 to 12 days per cycle, rather than continuous daily dosing. Therefore, the usage is intermittent and short-term by design, though the overall course of therapy may extend over a longer period as determined by a healthcare provider.


Q: Can Ova-Gest cause skin changes or acne?

Official regulatory documents list conditions generally attributed to progestins which may possibly occur, such as chloasma (skin discoloration) and rash. Specific reports of acne are not consistently highlighted as a common side effect in oral progesterone labels, but patients should report any concerning skin changes to their provider.


Q: Does Ova-Gest have any effect on blood pressure?

Some official drug information sources cite a moderate potential hazard for high blood pressure (hypertension) associated with progestogen use. Patients with a history of hypertension may require closer monitoring during therapy with this medication.


Q: What happens when a person stops taking Ova-Gest?

When used for secondary amenorrhea (absence of a period), stopping the drug is intended to cause a withdrawal bleed (a scheduled period) to begin within a few days after the last dose. This is a common and expected outcome for this indication.


Q: Is it normal to have a slight headache when starting this medication?

Headache is listed in official documents as a common side effect of this medication. Patients are advised to discuss the severity or persistence of any headaches with their prescribing healthcare professional.


Q: Has Ova-Gest been studied in older adults (seniors)?

Regulatory documents state that clinical data is insufficient to establish a differential response in geriatric patients. However, no geriatric-specific problems have been definitively documented to date, though caution is required due to the increased prevalence of underlying conditions.


Q: Does taking Ova-Gest at a specific time of day matter?

Yes, official instructions specify the capsule should be taken as a single dose at bedtime. This timing is explicitly chosen to align with the drug’s absorption profile and to minimize the awareness of potential central nervous system side effects like dizziness or drowsiness.


Q: Do I need to change my diet while using Ova-Gest?

Official guidance usually advises patients to discuss the use of the medicine with a healthcare professional regarding food, alcohol, or tobacco use. Food consumption is known to increase the absorption of the oral capsule, but the need for specific general dietary changes should be clarified with a healthcare professional.


Q: Are there any contraindications related to mental health conditions?

While severe depression is listed as a serious adverse event that requires medical attention, formal contraindications (absolute prohibitions) do not list mental health conditions. However, mood changes are a documented risk, and patients with a history of mood disorders may require closer monitoring as a precaution.


Q: Does Ova-Gest have any withdrawal symptoms?

For the indication of secondary amenorrhea, stopping the drug is intended to cause a withdrawal bleed (a period) within a few days after the last dose. Regulatory labels do not typically detail other non-menstrual withdrawal symptoms upon discontinuation.


Q: Can Ova-Gest be used by adolescents?

Official documents state that the safety and effectiveness of the oral capsule have not been established for the pediatric population, which includes adolescents under 18. Use in this age group would require specific clinical consideration and is not part of the current regulatory labeling.


Q: Is Ova-Gest affected by grapefruit or grapefruit juice?

Yes, official documents advise that grapefruit or grapefruit juice may increase the blood levels of progesterone. This is because the drug is metabolized by the CYP3A4 enzyme in the liver. Patients are advised to consult their healthcare provider regarding the consumption of grapefruit products while using this medication.


Q: What is the general consensus on the long-term safety of Ova-Gest?

The official documents state that long-term safety data remains limited. The most significant risks associated with prolonged progestin therapy (especially when used with estrogen) include an increased risk of thromboembolic events (blood clots) and breast cancer. Regulatory guidance recommends discussing the appropriate duration of therapy with a healthcare provider.


Q: Does Ova-Gest interact with alcohol?

Regulatory guidance advises patients to discuss the use of the medicine with a healthcare professional regarding alcohol use. This is primarily because both the medication and alcohol can cause drowsiness, and combining them may increase this effect.


Q: Is Ova-Gest known to cause any allergic reactions?

Yes, hypersensitivity to progesterone or any capsule ingredients is a formal contraindication (absolute prohibition). Symptoms like hives, rash, itching, or swelling of the face, tongue, or throat are signs of a potential allergic reaction that may necessitate immediate medical attention.


Q: Can men or non-female patients take Ova-Gest?

The medication is officially designated for use in Adult Women. The use of the oral formulation in male patients for any indication is considered off-label as safety, appropriate dosing, and clinical outcomes have not been adequately studied in that population.


Q: Is Ova-Gest safe to take while trying to conceive?

Progesterone is sometimes used by healthcare professionals in the treatment of conditions related to infertility (such as luteal phase deficiency) and in women undergoing assisted reproductive technology procedures. However, the oral capsule is generally contraindicated once pregnancy is confirmed, so usage while trying to conceive is typically recommended to be discussed with a specialist.


Q: Does Ova-Gest make birth control pills less effective?

The interaction section mentions that co-administration with other hormonal medicines may alter the overall hormonal balance and affect the actions of both treatments. Patients are generally advised to specifically discuss the use of any birth control pills with their healthcare professional to understand any potential combined effects.


Q: Can I take Ova-Gest if I have a history of liver problems?

Ova-Gest is contraindicated (absolutely prohibited) in individuals with severe liver disease or hepatic impairment. For patients with a documented history of liver problems, closer medical observation and monitoring by a healthcare professional is advised before and during treatment.


How should Ova-Gest be stored and disposed of?

The official documentation defines strict conditions for storing and disposing of Ova-Gest (oral micronized progesterone capsules).

Storage & Disposal Scope Labeled Regulatory Requirements
Storage Temperature Store at room temperature, typically 20 C to 25 C (68 F to 77 F); do not refrigerate or freeze.
Environmental Protection Keep the product away from excess heat and moisture and protect it from direct light.
Packaging Keep the medicine in the original container and ensure the container is tightly closed to maintain stability until the expiry date.
Child Safety The medication must be stored out of the sight and reach of children.
Disposal Instructions Do not keep outdated medicine. Dispose of unused or expired product and any waste material in accordance with local requirements; consult a pharmacist or healthcare professional for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ova-Gest found in:

A-Z Index: